MCID: SRC027
MIFTS: 56

Sarcoma, Synovial

Categories: Genetic diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Sarcoma, Synovial

MalaCards integrated aliases for Sarcoma, Synovial:

Name: Sarcoma, Synovial 57 13 13 44 40
Synovial Sarcoma 12 76 53 59 37 29 15 73
Synovialosarcoma 59
Sarcoma Synovial 55

Characteristics:

Orphanet epidemiological data:

59
synovial sarcoma
Inheritance: Not applicable; Age of onset: All ages;

HPO:

32
sarcoma, synovial:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 57 300813
Disease Ontology 12 DOID:5485
MeSH 44 D013584
NCIt 50 C3400
SNOMED-CT 68 302851001 63211008
Orphanet 59 ORPHA3273
UMLS via Orphanet 74 C0039101
ICD10 via Orphanet 34 C49.9
MedGen 42 C0039101
KEGG 37 H00050
SNOMED-CT via HPO 69 124975008
UMLS 73 C0039101

Summaries for Sarcoma, Synovial

NIH Rare Diseases : 53 Synovial sarcoma is a rare and aggressive soft tissue sarcoma. In the early stages of the condition, it may cause no noticeable signs or symptoms. However, as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit range of motion or cause numbness and/or pain if it presses on nearby nerves. Although synovial sarcoma does not have a clearly defined cause, genetic factors are believed to influence the development of this disease. Cells in these tumors are usually characterized by the presence of a translocation involving chromosomes X and 18. This translocation is specific to synovial sarcoma and is often used to diagnose the condition. Treatment generally includes a combination of surgery, radiation therapy and/or chemotherapy.

MalaCards based summary : Sarcoma, Synovial, also known as synovial sarcoma, is related to epithelioid cell synovial sarcoma and spindle cell synovial sarcoma. An important gene associated with Sarcoma, Synovial is SSX1 (SSX Family Member 1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Endometrial cancer. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, lung and kidney, and related phenotypes are synovial sarcoma and Increased shRNA abundance (Z-score > 2)

OMIM : 57 Synovial sarcomas, which represent approximately 10% of all soft tissue sarcomas, are aggressive spindle cell sarcomas containing in some cases areas of epithelial differentiation. They consistently show a specific t(X;18)(p11.2;q11.2), which usually represents either of 2 gene fusions, SYT (600192)-SSX1 (312820) or SYT-SSX2 (300192), encoding putative transcriptional proteins differing at 13 amino acid positions (summary by Ladanyi et al., 2002). Synovial sarcoma, according to the experience of Enzinger and Weiss (1983), is the fourth most common type of soft tissue sarcoma. It usually develops in adolescents and young adults, is more common in males than in females, and has no racial predilection. (300813)

Disease Ontology : 12 A synovium cancer which develops in the synovial membrane of the joints.

Wikipedia : 76 A synovial sarcoma (also known as: malignant synovioma) is a rare form of cancer which occurs primarily... more...

Related Diseases for Sarcoma, Synovial

Diseases related to Sarcoma, Synovial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
# Related Disease Score Top Affiliating Genes
1 epithelioid cell synovial sarcoma 33.0 SSX1 SSX2B
2 spindle cell synovial sarcoma 32.0 KIT KRT7 SS18 SSX1 SSX2 SSX2B
3 sarcoma 30.7 KIT SS18 SSX1 SSX2 SSX2B SSX3
4 mediastinum synovial sarcoma 11.1
5 solid adenocarcinoma with mucin production 11.0 KRT7 MUC1
6 jejunal cancer 11.0 KIT KRT7
7 reticular perineurioma 11.0 KIT MUC1
8 cervical adenoma malignum 11.0 HMGA2 KRT7
9 pseudo-meigs syndrome 11.0 CALB2 CDH1
10 lung acinar adenocarcinoma 11.0 CTNNB1 KRT7
11 mast-cell sarcoma 11.0 KIT VIM
12 linitis plastica 11.0 CDH1 KRT7
13 endosalpingiosis 10.9 KRT7 MUC1
14 ovarian fibrothecoma 10.9 CALB2 KIT
15 kidney hemangiopericytoma 10.9 SS18 SSX2B
16 large intestine adenocarcinoma 10.9 CDH1 CTNNB1 KRT7
17 malignant peritoneal mesothelioma 10.9 MUC1 VIM
18 female reproductive endometrioid cancer 10.9 CTNNB1 KRT7
19 ovarian serous cystadenofibroma 10.9 CALB2 MUC1
20 adenomyoma 10.9 CTNNB1 KRT7 MUC1
21 adenoid squamous cell carcinoma 10.9 CDH1 KRT7 VIM
22 gynandroblastoma 10.9 CALB2 VIM
23 parachordoma 10.9 KRT7 MUC1 VIM
24 bile duct mucoepidermoid carcinoma 10.9 KRT7 MUC1
25 extraskeletal mesenchymal chondrosarcoma 10.9 SSX1 SSX2B
26 nodular hidradenoma 10.9 KRT7 MUC1 VIM
27 sclerosing hemangioma 10.9 CTNNB1 KRT7 MUC1
28 papillary tumor of the pineal region 10.9 MUC1 VIM
29 intrahepatic bile duct adenoma 10.9 KRT19 KRT7
30 middle ear adenoma 10.9 KRT7 MUC1
31 lymphoepithelioma-like carcinoma 10.9 CDH1 KRT7 MUC1
32 spiradenoma 10.9 KRT7 MUC1 VIM
33 hidradenoma 10.9 KRT7 MUC1 VIM
34 anal gland adenocarcinoma 10.9 KRT19 KRT7
35 proliferating trichilemmal cyst 10.9 KRT19 KRT7
36 conventional fibrosarcoma 10.9 CTNNB1 KIT MDM2
37 organ system benign neoplasm 10.9 CTNNB1 KIT KRT7
38 perivascular epithelioid cell tumor 10.9 KIT MUC1 VIM
39 lobular neoplasia 10.9 CDH1 CTNNB1 MUC1
40 mucinous cystadenocarcinoma 10.9 KRT7 MUC1 VIM
41 retroperitoneal fibrosis 10.9 MDM2 VIM
42 perineurioma 10.8 KIT MUC1 VIM
43 malignant ovarian surface epithelial-stromal neoplasm 10.8 CDH1 KRT7 MUC1
44 ovary epithelial cancer 10.8 CDH1 KRT7 MUC1
45 papillary craniopharyngioma 10.8 CTNNB1 KRT7
46 spindle cell lipoma 10.8 MDM2 VIM
47 regional odontodysplasia 10.8 KRT19 VIM
48 fibromatosis 10.8 CTNNB1 KIT VIM
49 secretory meningioma 10.8 KRT7 MUC1 VIM
50 chondroid chordoma 10.8 CDH1 MUC1 VIM

Graphical network of the top 20 diseases related to Sarcoma, Synovial:



Diseases related to Sarcoma, Synovial

Symptoms & Phenotypes for Sarcoma, Synovial

Clinical features from OMIM:

300813

Human phenotypes related to Sarcoma, Synovial:

32
# Description HPO Frequency HPO Source Accession
1 synovial sarcoma 32 HP:0012570

GenomeRNAi Phenotypes related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

26 (show all 50)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.29 SSX2B SSX2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.29 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.29 VIM
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.29 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.29 CTNNB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.29 IGF1R
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.29 SSX1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.29 IGF1R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.29 VIM
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.29 SSX2B SSX3 SSX2 SSX4 SSX1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.29 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.29 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.29 IGF1R
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.29 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.29 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.29 CTNNB1 VIM IGF1R
17 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.29 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.29 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.29 CTNNB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.29 IGF1R
21 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.29 SSX2B SSX3 IGF1R SSX4
22 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.29 SSX1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.29 VIM
24 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.29 SSX2B SSX2 VIM KIT
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.29 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.29 IGF1R
27 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.29 IGF1R SSX2B SSX3 CTNNB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.29 CTNNB1 SSX4
29 Increased shRNA abundance (Z-score > 2) GR00366-A-51 10.29 SSX4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.29 SSX1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.29 VIM SSX1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.29 CTNNB1 SSX4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.29 CTNNB1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.29 CTNNB1 IGF1R
35 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.29 SSX2B SSX3 SSX2
36 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.29 SSX3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.29 CTNNB1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.29 SSX2B SSX2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.29 SSX4
40 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.29 IGF1R VIM KIT
41 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.29 KIT
42 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10.29 SSX3
43 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.29 KIT
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 9.65 SSX4
45 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.65 SSX3 SSX4 VIM SSX2B
46 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.65 SSX2B
47 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.65 VIM
48 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.65 SSX4
49 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.65 SSX2B
50 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.65 VIM

MGI Mouse Phenotypes related to Sarcoma, Synovial:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.5 CDH1 CTNNB1 ELF3 IGF1R KIT KRT19
2 embryo MP:0005380 9.23 MDM2 SS18 VIM CDH1 CTNNB1 IGF1R

Drugs & Therapeutics for Sarcoma, Synovial

Drugs for Sarcoma, Synovial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
9
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 2019 457193
10
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
11
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
12
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
13
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
14
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
15
Idarubicin Approved Phase 3 58957-92-9 42890
16
Cyproheptadine Approved Phase 3 129-03-3 2913
17
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
18
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
19 Trofosfamide Investigational Phase 3 22089-22-1
20 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
22 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
24
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
27 Etoposide phosphate Phase 3,Phase 2
28 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Not Applicable
29 Antimitotic Agents Phase 3,Phase 2
30 Antirheumatic Agents Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
32 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
33 Antimetabolites Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
35 Antiviral Agents Phase 3,Phase 2,Not Applicable
36 Anti-Allergic Agents Phase 3
37 Antipruritics Phase 3
38 Dermatologic Agents Phase 3
39 Gastrointestinal Agents Phase 3
40 Histamine Antagonists Phase 3
41 Histamine H1 Antagonists Phase 3
42
Histamine Phosphate Phase 3 51-74-1 65513
43 Neurotransmitter Agents Phase 3
44 Serotonin Agents Phase 3
45 Serotonin Antagonists Phase 3
46
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
47
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
48
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
49
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
50
Everolimus Approved Phase 1, Phase 2,Phase 2 159351-69-6 6442177

Interventional clinical trials:

(show top 50) (show all 101)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
6 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
7 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
11 Synovate Study for Synovial Sarcoma, Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma Recruiting NCT03520959 Phase 3
12 A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL 3818;Dacarbazine
13 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
14 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
15 Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma Recruiting NCT00876031 Phase 3 trofosfamide, idarubicin, etoposide
16 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
17 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
18 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
19 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
20 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
21 Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma Completed NCT00052754 Phase 2 gefitinib
22 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma Completed NCT00104949 Phase 2
23 Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma Completed NCT01281865 Phase 1, Phase 2 everolimus;imatinib mesylate
24 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
25 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
26 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
27 Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure Completed NCT01136499 Phase 2 LBH589 (Panobinostat®)
28 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
29 Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
30 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
31 Ixabepilone in Treating Young Patients With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
32 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
33 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
34 Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood Completed NCT00030667 Phase 2 imatinib mesylate
35 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
36 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
37 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
38 Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma Completed NCT00297258 Phase 2 pazopanib
39 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
40 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
41 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
42 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
43 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
44 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
45 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
46 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
47 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
48 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
49 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
50 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate

Search NIH Clinical Center for Sarcoma, Synovial

Cochrane evidence based reviews: sarcoma, synovial

Genetic Tests for Sarcoma, Synovial

Genetic tests related to Sarcoma, Synovial:

# Genetic test Affiliating Genes
1 Synovial Sarcoma 29 SSX1 SSX2

Anatomical Context for Sarcoma, Synovial

MalaCards organs/tissues related to Sarcoma, Synovial:

41
T Cells, Lung, Kidney, Bone, Brain, Testis, Testes

Publications for Sarcoma, Synovial

Articles related to Sarcoma, Synovial:

(show top 50) (show all 917)
# Title Authors Year
1
Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases. ( 29225052 )
2018
2
Mediastinal monophasic synovial sarcoma with pericardial extension causing hemodynamic instability. ( 29765618 )
2018
3
Establishment and characterization of the NCC-SS1-C1 synovial sarcoma cell line. ( 29450702 )
2018
4
Extracellular vesicle-encapsulated microRNA-761 enhances pazopanib resistance in synovial sarcoma. ( 29191657 )
2018
5
Primary Gastric Synovial Sarcoma Mimicking a Gastrointestinal Stromal Tumor (GIST) : Gastric Synovial Sarcoma. ( 29313287 )
2018
6
Laser capture microdissection for detecting the expression of epithelial-mesenchymal transition-related genes in epithelial and spindle cells of paraffin-embedded formalin-fixed biphasic synovial sarcoma. ( 29575169 )
2018
7
Synovial sarcoma mimicking a thoracic dumbell schwannoma- a case report. ( 29446979 )
2018
8
The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients. ( 29280411 )
2018
9
Treatment of cardiac synovial sarcoma: experience of two cases. ( 29970129 )
2018
10
Primary Cardiac Synovial Sarcoma: A Case Report. ( 28469690 )
2017
11
Monophasic synovial sarcoma of the greater omentum: case report and review of literature. ( 28660813 )
2017
12
TLE-1-Positive Angiomatoid Fibrous Histiocytoma Mimicking Synovial Sarcoma. ( 28248724 )
2017
13
Primary Cystic Pleuropulmonary Synovial Sarcoma Presenting as Recurrent Pneumothorax. ( 28868028 )
2017
14
Whorling cellular perineurioma: A previously undescribed variant closely mimicking monophasic fibrous synovial sarcoma. ( 28325366 )
2017
15
PAX8-positive Biphasic Synovial Sarcoma Expressing Hormonal Receptors. ( 28248726 )
2017
16
Cytologic features of primary monophasic synovial sarcoma of the thyroid gland. ( 29259650 )
2017
17
Pericardial Synovial Sarcoma Followed Up With Contrast-Enhanced PET-CT. ( 28195904 )
2017
18
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. ( 28085948 )
2017
19
The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteilsarkom Studie) trials. ( 27621063 )
2017
20
A clinicopathologic study on SS18 fusion positive head and neck synovial sarcomas. ( 28249647 )
2017
21
High-risk gastrointestinal stromal tumour (GIST) and synovial sarcoma display similar angiogenic profiles: a nude mice xenograft study. ( 28386296 )
2017
22
Primary Synovial Sarcoma of External Auditory Canal: A Case Report. ( 28948118 )
2017
23
Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. ( 27993576 )
2017
24
ATR Is a Therapeutic Target in Synovial Sarcoma. ( 29038346 )
2017
25
Influence of neoadjuvant chemotherapy on prognosis of patients with synovial sarcoma. ( 28494784 )
2017
26
Biphasic synovial sarcoma of the epiglottis: Case report and literature review. ( 28689931 )
2017
27
Metachronuous Synovial Sarcoma After Treatment of Mixed Germ Cell Tumor in a Child of Complet Gonodal Dysgenesis. ( 28836496 )
2017
28
The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma. ( 26905812 )
2016
29
Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas. ( 27439614 )
2016
30
Role, timing and technique of radiotherapy in pediatric pleuropulmonary synovial sarcoma. ( 27659844 )
2016
31
Primary Mediastinal Synovial Sarcoma with subsequent development of Primary Adenoid Cystic Carcinoma of Lung presenting as superior vena cava syndrome. ( 26992072 )
2016
32
The First Ever Reported Case of Primary Synovial Sarcoma of Scalp. ( 27446625 )
2016
33
Synovial sarcoma presenting as colonic intussusception in a child. ( 27572305 )
2016
34
The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas: a validation study. ( 26520417 )
2016
35
Intravascular Biphasic Synovial Sarcoma: The Beneficial Role of Adjuvant Treatment Approach in the Pre-metastatic Stage. ( 27190730 )
2016
36
Primary pulmonary monophasic synovial sarcoma: Evading diagnosis. ( 26612959 )
2016
37
Synovial sarcoma of the hypopharynx in a pediatric patient: Case report. ( 27649458 )
2016
38
A case report of pancreatic metastasis from synovial sarcoma successfully treated by metastasectomy with adjuvant chemotherapy. ( 27684804 )
2016
39
The interaction of hepatoma-derived growth factor and I^-catenin promotes tumorigenesis of synovial sarcoma. ( 26842923 )
2016
40
Primary Synovial Sarcoma of the Kidney with Inferior Vena Caval Thrombus. ( 27651698 )
2016
41
Monophasic synovial sarcoma of posterior pharyngeal wall: a rare case report with unique reconstruction using lateral trapezius flap. ( 27328959 )
2016
42
Synovial Sarcoma With Myoid Differentiation. ( 27106779 )
2016
43
Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma. ( 27779808 )
2016
44
Occult primary pulmonary synovial sarcoma presenting as recurrent spontaneous pneumothorax and explosive progression. ( 27995774 )
2016
45
Essential role of mitogen-activated protein kinases in IL-17A-induced MMP-3 expression in human synovial sarcoma cells. ( 26850593 )
2016
46
Diagnostic Approach to Synovial Sarcoma of the Head and Neck Illustrated by Two Cases Arising in the Face and Oral Cavity. ( 27195266 )
2016
47
Biphasic synovial sarcoma with prominent cavernous hemangioma-like stroma. ( 27988941 )
2016
48
Giant primary synovial sarcoma of the anterior mediastinum: A case report and review of literature. ( 26856298 )
2016
49
Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor. ( 27353471 )
2016
50
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. ( 27391784 )
2016

Variations for Sarcoma, Synovial

Cosmic variations for Sarcoma, Synovial:

9
(show all 20)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM43687 TP53 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 13
2 COSM11333 TP53 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 13
3 COSM4774989 SH2B3 soft tissue,leg,sarcoma,NS c.232G>A p.E78K 12:111418377-111418377 13
4 COSM6954536 NUP93 soft tissue,leg,sarcoma,NS c.116C>T p.A39V 16:56748363-56748363 13
5 COSM2923082 ANKRD11 soft tissue,leg,sarcoma,NS c.2882G>T p.R961L 16:89283660-89283660 13
6 COSM121083 soft tissue,leg,sarcoma,NS c.220C>T p.Q74* 17:7675113-7675113 13
7 COSM1640840 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 13
8 COSM307279 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 13
9 COSM2744872 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 13
10 COSM3937613 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 13
11 COSM307282 soft tissue,leg,sarcoma,NS c.362A>G p.H121R 17:7674890-7674890 13
12 COSM121082 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 13
13 COSM121084 soft tissue,leg,sarcoma,NS c.103C>T p.Q35* 17:7675113-7675113 13
14 COSM3388198 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 13
15 COSM121081 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 13
16 COSM307280 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 13
17 COSM307281 soft tissue,leg,sarcoma,NS c.245A>G p.H82R 17:7674890-7674890 13
18 COSM480 HRAS soft tissue,lower leg,synovial sarcoma,NS c.34G>A p.G12S 11:534289-534289 8
19 COSM1745010 MYOD1 soft tissue,lower leg,rhabdomyosarcoma,spindle cell c.365T>G p.L122R 11:17720147-17720147 4
20 COSM33732 IDH2 soft tissue,upper leg,haemangioma,spindle cell c.515G>T p.R172M 15:90088606-90088606 4

Copy number variations for Sarcoma, Synovial from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 120197 18 21850214 21924609 Translate SS18 Synovial sarcoma

Expression for Sarcoma, Synovial

Search GEO for disease gene expression data for Sarcoma, Synovial.

Pathways for Sarcoma, Synovial

Pathways related to Sarcoma, Synovial according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

GO Terms for Sarcoma, Synovial

Cellular components related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 CALB2 CTNNB1 ELF3 HMGA2 KRT7 MAGEA1
2 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 9.96 CTNNB1 ELF3 HMGA2 MAGEA1 SS18 SSX1
2 positive regulation of gene expression GO:0010628 9.72 CTNNB1 HMGA2 KIT MDM2 VIM
3 transcription, DNA-templated GO:0006351 9.65 CTNNB1 ELF3 HMGA2 MAGEA1 SS18 SSX1
4 entry of bacterium into host cell GO:0035635 9.37 CDH1 CTNNB1
5 cellular response to indole-3-methanol GO:0071681 9.16 CDH1 CTNNB1
6 negative regulation of nucleic acid-templated transcription GO:1903507 9.02 SSX1 SSX2 SSX2B SSX3 SSX4

Molecular functions related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 CDH1 CTAG1B CTNNB1 ELF3 HMGA2 IGF1R
2 transcription corepressor activity GO:0003714 9.02 SSX1 SSX2 SSX2B SSX3 SSX4

Sources for Sarcoma, Synovial

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....